Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch
Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...
verywellhealth17h
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
Dallas Innovates5d
Alpha Cognition Inks $44M Licensing Agreement With China’s CMS for Alpha’s ZUNVEYL Alzheimer’s Drug
The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...
Business Wire7d
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild ...
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing ...
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and ...
The Globe and Mail1mon
Alpha Cognition Announces Partial Exercise of Over-allotment Option
Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders ...
AOL7d
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition remains on track to launch Zunveyl in the United States in Q1 2025. The company will provide a corporate update and present its Launch Strategy on January 28, 2025.
Nasdaq6d
Alpha Cognition, China Medical System enter exclusive Zunveyl licensing pact
Alpha Cognition (ACOG) and China Medical System announced an exclusive licensing agreement for the development, manufacturing and commercialization of Zunveyl in Asia, Australia and New Zealand.